The MMRF provides CME-accredited educational programs for healthcare professionals to learn more about multiple myeloma as well as current and emerging treatment options, including clinical trials from key leaders in myeloma. Access up-to-date information.
Current Obstacles in Myeloma Management: Debating the Evidence
Co-Chairs: Paul Richardson, MD, and A. Keith Stewart, MBChB
Faculty: Faith E. Davies, MBBCh, MD; Rafael Fonseca, MD; Amrita Y. Krishnan, MD; Saad Z. Usmani, MD
In this lively online CME activity, members of our expert faculty square off to debate several key issues relating to multiple myeloma patient care:
• Should smoldering myeloma be treated?
• Can we apply risk-adapted therapy to newly diagnosed multiple myeloma patients?
• Transplant (early) or no transplant (delayed)?
• When should novel investigational immune-based therapies be considered in the relapsed/refractory setting?
This activity also features panel discussions on the best strategies for incorporating new and emerging myeloma drugs and combinations into practice, with a focus on personalizing treatment and developing plans to prepare for relapse.
With the number and nature of multiple myeloma management options continuing to expand, how can myeloma nurses expect to keep pace and provide their patients the best possible care? By playing a round or two of Myeloma Masters: The Ultimate Myeloma Patient Care Quiz Show! This accredited interactive CNE activity—under the guise of a 70s-era TV game show—tests players’ knowledge of current and emerging myeloma patient care best practices while using a range of multimedia hints to present and review critical, evidence-based, clinical content. Players gain points by correctly answering questions—earning praise or ribbing from our smarmy host—as they try to earn the coveted title of Myeloma Master. Play a round today!
Developed to help hematologist-oncologists keep pace with new advancements in multiple myeloma management, this CME-certified video roundtable features a panel of myeloma experts and reviews a number of strategies for individualizing treatment plans based on genomics and risk stratification to achieve durable remission while minimizing toxicity.